NYSE:GLS Gelesis Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Gelesis Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.60 -0.09 (-5.33%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$1.50▼$1.7850-Day Range$1.60▼$5.3552-Week Range$1.50▼$12.23Volume804,427 shsAverage Volume156,408 shsMarket Capitalization$115.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter. Email Address GLS Stock Forecast (MarketRank)Overall MarketRank™0.33 out of 5 starsMedical Sector1323rd out of 1,411 stocksPharmaceutical Preparations Industry646th out of 672 stocksAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Gelesis. Previous Next 0.0 Community Rank Outperform VotesGelesis has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGelesis has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Gelesis and other stocks. Vote “Outperform” if you believe GLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGelesis does not currently pay a dividend.Dividend GrowthGelesis does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Gelesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,019.00 in company stock and sold $0.00 in company stock. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Gelesis (NYSE:GLS)Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.Read More GLS Stock News HeadlinesJune 21, 2022 | seekingalpha.comGelesis announces additional $15M pre-order for PlenityJune 20, 2022 | americanbankingnews.comInsider Buying: Gelesis Holdings, Inc. (NYSE:GLS) Director Acquires $48,018.75 in StockJune 5, 2022 | finance.yahoo.comOver the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New StudyJune 4, 2022 | finance.yahoo.comMicrobiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary HydrogelMay 28, 2022 | nasdaq.comGelesis Holdings, Inc. Common Stock (GLS)May 27, 2022 | investing.comGelesis Holdings Inc (GLS)May 18, 2022 | finance.yahoo.comGelesis to Participate in Upcoming Investor ConferencesMay 14, 2022 | seekingalpha.comGelesis Holdings' (GLS) CEO Yishai Zohar on Q1 2022 Results - Earnings Call TranscriptMay 13, 2022 | seekingalpha.comGelesis Holdings GAAP EPS of -$0.70, revenue of $7.51MMay 9, 2022 | finance.yahoo.comGelesis to Report First Quarter 2022 Financial Results on May 12, 2022May 4, 2022 | finance.yahoo.comClinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 DiabetesApril 29, 2022 | finance.yahoo.comGelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New StudySee More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:GLS CUSIPN/A CIK1805087 Webcapstarspac.com Phone512-340-7800FaxN/AEmployees2Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/26/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12.90 million Net MarginsN/A Pretax Margin-0.73% Return on Equity-179.96% Return on Assets15.16% Debt Debt-to-Equity Ratio3.38 Current Ratio1.42 Quick Ratio1.10 Sales & Book Value Annual Sales$11.19 million Price / Sales10.35 Cash FlowN/A Price / Cash FlowN/A Book Value($7.76) per share Price / Book-0.21Miscellaneous Outstanding Shares72,390,000Free FloatN/AMarket Cap$115.82 million OptionableNot Optionable Beta0.95 Gelesis Frequently Asked Questions How has Gelesis' stock performed in 2022? Gelesis' stock was trading at $6.53 at the beginning of 2022. Since then, GLS stock has decreased by 75.5% and is now trading at $1.60. View the best growth stocks for 2022 here. When is Gelesis' next earnings date? Gelesis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Gelesis. How were Gelesis' earnings last quarter? Gelesis Holdings, Inc. (NYSE:GLS) issued its earnings results on Thursday, May, 12th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $7.51 million for the quarter. View Gelesis' earnings history. What guidance has Gelesis issued on next quarter's earnings? Gelesis updated its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $58.00 million-$58.00 million. Who are Gelesis' key executives? Gelesis' management team includes the following people: Mr. Yishai Zohar, Founder, Pres, CEO & Director (Age 59, Pay $689.95k)Mr. Elliot Maltz CPA, CFO & Treasurer (Age 37, Pay $486.26k)Dr. David Pass Pharm.D., COO & Chief Commercial Officer (Age 53)Mr. David Abraham J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56, Pay $494.73k)Dr. Elaine Chiquette Pharm.D., Chief Scientific Officer (Age 55)Dr. Harry L. Leider FACPE, M.B.A., M.D., MBA, Chief Medical Officer (Age 63)Ms. Joy Bauer M.S., MS, RDN, Chief Nutrition Officer of Plenity Who are some of Gelesis' key competitors? Some companies that are related to Gelesis include Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Altimmune (ALT), Protagonist Therapeutics (PTGX), Imago BioSciences (IMGO), Centessa Pharmaceuticals (CNTA), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), Edgewise Therapeutics (EWTX), Arbutus Biopharma (ABUS), Karyopharm Therapeutics (KPTI), Esperion Therapeutics (ESPR), Tango Therapeutics (TNGX) and Aerovate Therapeutics (AVTE). View all of GLS's competitors. What is Gelesis' stock symbol? Gelesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "GLS." Who are Gelesis' major shareholders? Gelesis' stock is owned by many different institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (1.61%), Vanguard Group Inc. (1.16%), BlackRock Inc. (0.82%), Beacon Pointe Advisors LLC (0.16%), State Street Corp (0.16%) and Northern Trust Corp (0.11%). View institutional ownership trends for Gelesis. Which major investors are buying Gelesis stock? GLS stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Vanguard Group Inc., BlackRock Inc., Beacon Pointe Advisors LLC, State Street Corp, Northern Trust Corp, Northeast Financial Consultants Inc, and Goldman Sachs Group Inc.. View insider buying and selling activity for Gelesis or or view top insider-buying stocks. How do I buy shares of Gelesis? Shares of GLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Gelesis' stock price today? One share of GLS stock can currently be purchased for approximately $1.60. How much money does Gelesis make? Gelesis (NYSE:GLS) has a market capitalization of $115.82 million and generates $11.19 million in revenue each year. How many employees does Gelesis have? Gelesis employs 2 workers across the globe. How can I contact Gelesis? Gelesis' mailing address is 405 WEST 14TH STREET, AUSTIN TX, 78701. The official website for Gelesis is capstarspac.com. The company can be reached via phone at 512-340-7800 or via email at 0. This page (NYSE:GLS) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here